Friday 6 November 2026 Export MDGL’s income statement to Excel — free account

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.

Revenue: +50.1%
EPS: +147.3%
Free cash flow: +53.5%
Total debt: +0.45%

Quarter to September 2026, against a year earlier

397.03 3.07 −0.77%

Follow MDGL

Alert me

Market cap: $9.3B
P/E: 0.0×
Fwd P/E: −68.8×
Dividend yield: —
F-score: n/a
Altman Z: 10.48
Beneish M: 0.50
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Madrigal Pharmaceuticals, Inc. (MDGL) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Madrigal Pharmaceuticals, Inc. (MDGL) trades at a P/S ratio of 8.2×. Over the past ten years it has ranged from 0.0× (March 2025) to 30.2× (April 2025); the current reading is higher than 87% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/MDGL/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Madrigal Pharmaceuticals, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/MDGL/metrics/ps-ratio">Madrigal Pharmaceuticals, Inc. (MDGL) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	13.6×	—
FY2024	0.0×	—

Period	P/S ratio	Change
Sep 2026	10.3×	(15.31%)
Jun 2026	12.2×	(9.17%)
Mar 2026	13.4×	(1.55%)
Dec 2025	13.6×	(22.79%)
6 more quarters	Free account

Against its own ten years

Low 0.0× High 30.2×

Ten-year median 0.0×

Current reading's percentile 87

Company	P/S ratio
CAI Caris Life Sciences,�Inc. compare	7.1×
MDGL Madrigal Pharmaceuticals, Inc.	8.2×
TGTX TG Therapeutics, Inc. compare	10.3×
TWST Twist Bioscience Corporation compare	17.6×
KRYS Krystal Biotech, Inc. compare	18.9×
PTGX Protagonist Therapeutics, Inc. compare	31.7×
IBRX ImmunityBio, Inc. compare	51.0×
CYTK Cytokinetics, Incorporated compare	64.4×
SYRE Spyre Therapeutics, Inc. compare	8,160×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Madrigal Pharmaceuticals, Inc. (MDGL) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on MDGL

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on MDGL

Stockrow Weekly